Oxford BioMedica is a biopharmaceutical company specializing in the development and commercialization of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax

TroVax

TroVax is a cancer vaccine being developed by Oxford BioMedica. No cancer vaccines have been proven to cure cancer or extend life yet, but TroVax is recruiting patients for 3 human trials.TroVax uses a tumor-associated antigen, 5T4, with a pox virus vector...

, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development in
collaboration with Sanofi-Aventis

Sanofi-Aventis

Sanofi S.A. is a multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the...

. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share price
The Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease

Parkinson's disease

Parkinson's disease is a degenerative disorder of the central nervous system...

 and retinopathy

Retinopathy

Retinopathy is a general term that refers to some form of non-inflammatory damage to the retina of the eye. Frequently, retinopathy is an ocular manifestation of systemic disease.-Pathophysiology:Causes of retinopathy are varied:...

. The company’s early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy

Spinal muscular atrophy

Spinal Muscular Atrophy is a neuromuscular disease characterized by degeneration of motor neurons, resulting in progressive muscular atrophy and weakness. The clinical spectrum of SMA ranges from early infant death to normal adult life with only mild weakness...

 and AIDS

AIDS

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome is a disease of the human immune system caused by the human immunodeficiency virus...

.

Finance

To date, the Company has raised a total of £137 million to fund its research and clinical programmes.
The IPO on the Alternative Investment Market of the London Stock Exchange in December 1996 raised £5.1 million.

A further £6 million was raised by a rights issue and placing in March/April 1998, £3.6 million by a rights issue in March 1999, £5.2 million in a Placing in January 2000 and £8.8 million in a Placing in August 2000.

Oxford BioMedica’s move to the official list of the London Stock Exchange was completed in April 2001 along with a £35.5 million fund raising, before costs, from a placing and open offer.

A Rights Issue for £22.1 million, before costs, was completed in October 2003. A further share offering in December 2005 raised £30.1 million before expenses, including an investment of £2.9 million by Sigma-Aldrich
. A placing and open offer in December 2010 raised £20 million.